Increasing knowledge of the cancer glycome and the need for new options to overcome resistance to immune checkpoint inhibitors are leading to an expansion of glycoimmunology. Stanford University professor Carolyn Bertozzi demonstrated that cell-surface glycans may be tagged to become targetable glyco-immune checkpoints. Read More
Researchers from Bridge Biotherapeutics Inc. have presented the discovery and preclinical characterization of BBT-4437, a novel brain-penetrable and reversible pan-transcriptional enhancer factor (TEAD) inhibitor, designed to target the Hippo signaling pathway in solid tumors. Read More
Researchers from Inventage Lab Inc. have presented preclinical data for its naltrexone-loaded microspheres, named IVL-3004, developed as long-acting injectable using the proprietary IVL-Drugfluidic technology platform. Read More
Qnovia Inc. has entered into a drug development collaboration with the University of Virginia (UVA) to advance novel inhaled drug candidates. Read More
Scripps Research Institute has disclosed transcriptional enhancer factor (TEAD) inhibitors reported to be useful for the treatment of cancer. Read More
Activated phosphoinositide 3-kinase δ syndrome type 1 (APDS1) is a rare disease caused by gain-of-function (GOF) mutations in the PIK3CD gene that presents with combined immunodeficiency due to decreases in IgA, IgG, naive CD4 and naive CD8 cells. Nearly all APDS1 patients suffer from recurrent respiratory tract infections with most presenting with bronchiectasis and chronic viral infections. Read More
Antibody-drug conjugates (ADCs) are effective anti-cancer agents in a wide variety of solid and hematologic cancers. CD30 (TNFRSF8), a member of the TNF receptor superfamily is the target of antibody drug conjugate Adcetris (brentuximab vedotin/BV, Seagen Inc.) approved for use in multiple CD30-expressing lymphomas. Read More
Tencent Technology (Shenzhen) Co. Ltd. has synthesized lysine-specific histone demethylase 1A (KDM1A; LSD1) inhibitors reported to be useful for the treatment of cancer. Read More
Sab Biotherapeutics Inc. has obtained human research ethics committee (HREC) approval in Australia to commence a first-in-human phase I trial investigating SAB-142 for type 1 diabetes. Read More
Chemocentryx Inc. has divulged chemokine CXCR6 receptor antagonists reported to be useful for the treatment of cancer, autoimmune hepatitis, ischemia-reperfusion injury, myocardial ischemia, autoimmune disease and inflammatory disorders. Read More
Vaxcyte Inc. has received FDA clearance of its IND application for VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease. Read More
Mindrank AI Co. Ltd. has described macroheterocyclic compounds acting as ALK mutant and ROS1 inhibitors reported to be useful for the treatment of cancer and immunological disorders. Read More
